β-blockers are effective antihypertensive agents and, together with diuretics, have been the
cornerstone of pioneering studies showing their benefits on cardiovascular morbidity and …

Although β-blockers have been previously shown to effectively reduce blood pressure (BP)
and have been used for hypertension treatment for over 40 years, their effect on …

Carvedilol is a novel antihypertensive agent. It is a multiple-action neurohormonal
antagonist with a beta-adrenoceptor blocking effect combined with a vasodilating action …

National guidelines recommend β‐blockers as second step agents after diuretic therapy in
patients without compelling indications despite little clinical trial evidence of cardiovascular …

Synopsis Carvedilol is a β-adrenoceptor antagonist which also causes peripheral
vasodilation primarily via α 1-adrenergic blockade. Carvedilol produces its antihypertensive …

Importance of the field: Carvedilol, a non-selective β-blocker, has recently drawn attention
because of its therapeutic benefits over other prescribed analogues for the treatment of …

In an open clinical study, long-term efficacy and safety of carvedilol were investigated in 154
patients with essential hypertension WHO I-II and diastolic blood pressure (BP) between 95 …

Carvedilol (Fig. 1) is a novel multiple action drug that has recently been introduced to the
market for the treatment of mild to moderate hypertension (3, lO-12). In extensive clinical …

Carvedilol (Fig. 1) is a novel multiple action drug that has recently been introduced to the
market for the treatment of mild to moderate hypertension (7, 8, 2426). In extensive clinical …

Establishing the overall efficacy or safety of a drug requires a unified methodological
approach and analysis of all clinical trials to be included. As an example, this paper presents …